A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice
- Registration Number
- NCT02545465
- Lead Sponsor
- Bayer
- Brief Summary
The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life clinical practice.
In addition, this study will describe patient demographics and reason for switching
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 125
Inclusion Criteria
- Female and male adult patients diagnosed with PAH or inoperable/recurrent/persistent CTEPH who have been switched from a PH treatment (i.e. Endothelin Receptor Antagonist(ERAs), Phosphodiesterase-5 inhibitor(PDE5i) or Prostacyclin Analog (PCA) to Adempas
Read More
Exclusion Criteria
- Patients participating in an investigational program with interventions outside of routine clinical practice
- Patients who have not switched their therapy from an Endothelin Receptor Antagonist (ERA) or Prostacyclin Analog (PCA) but received Adempas purely as an add-on therapy
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description BAY63-2521 Riociguat (Adempas, BAY63-2521) Patients who have been switched from a Pulmonary Hypertension treatment to Adempas
- Primary Outcome Measures
Name Time Method Starting Dose Up to a total of 8 weeks of titration period Dose Increments Up to a total of 8 weeks of titration period Final Dose Up to a total of 8 weeks of titration period
- Secondary Outcome Measures
Name Time Method